Cromwell Holdings LLC Has $677,000 Holdings in Johnson & Johnson (NYSE:JNJ)

Cromwell Holdings LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 8.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,681 shares of the company’s stock after selling 453 shares during the period. Cromwell Holdings LLC’s holdings in Johnson & Johnson were worth $677,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. Mattern Capital Management LLC increased its holdings in Johnson & Johnson by 4.1% during the 4th quarter. Mattern Capital Management LLC now owns 51,095 shares of the company’s stock valued at $7,389,000 after purchasing an additional 2,031 shares in the last quarter. ING Groep NV grew its holdings in shares of Johnson & Johnson by 58.5% during the fourth quarter. ING Groep NV now owns 524,810 shares of the company’s stock worth $75,898,000 after purchasing an additional 193,689 shares during the last quarter. Flossbach Von Storch SE increased its stake in shares of Johnson & Johnson by 0.4% in the fourth quarter. Flossbach Von Storch SE now owns 6,529,296 shares of the company’s stock valued at $944,267,000 after buying an additional 28,814 shares in the last quarter. Morningstar Investment Management LLC raised its holdings in shares of Johnson & Johnson by 5.5% in the fourth quarter. Morningstar Investment Management LLC now owns 5,855 shares of the company’s stock valued at $847,000 after buying an additional 303 shares during the last quarter. Finally, First Bank & Trust acquired a new position in Johnson & Johnson during the 4th quarter worth about $936,000. Institutional investors own 69.55% of the company’s stock.

Insider Activity

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.16% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

JNJ has been the subject of several research reports. Wolfe Research initiated coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective for the company. Guggenheim raised their price target on shares of Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a report on Monday, February 3rd. Citigroup reduced their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Finally, Stifel Nicolaus cut their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $170.67.

Johnson & Johnson Stock Up 1.7 %

Johnson & Johnson stock opened at $162.35 on Monday. The firm has a market capitalization of $390.87 billion, a price-to-earnings ratio of 24.41, a PEG ratio of 2.56 and a beta of 0.52. The company’s 50 day simple moving average is $148.93 and its 200 day simple moving average is $155.86. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.29 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.06%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.